ClinicalTrials.gg
CompletedNCT03288038Updated Sep 19, 2017

The Efficacy and Safety of Combination Therapy of Rosuvastatin and Ezetimibe and Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia

A Phase 3 interventional study of Rosuvastatin and Ezetimibe in Hypercholesterolemia, sponsored by Shin Poong Pharmaceutical Co. Ltd.. Completed at 20 sites in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2017-09-19.

Sponsored by Shin Poong Pharmaceutical Co. Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 10 months after the study started (first participant enrolled Oct 2014, registered Aug 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
382
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.

Enrollment
24th of 97
382 · median 148
Started
2014
with 1 other
Phase 3
50 of 98
1 open now
Registered
80th of 98
by date

Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 24th largest by enrollment of the 97 interventional ones that give a count, is one of 2 that started in 2014, is one of 50 in phase 3, and was the 80th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ezetimibe

Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing ezetimibe in Hypercholesterolemia, or all of them as a file.
02

Study summary

A Multi-center, Randomized, Double-blind, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of Rosuvastatin and Ezetimibe and Rosuvastatin Monotherapy in Patients with Primary Hypercholesterolemia

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 19 years or older
  2. Patients with primary hypercholesterolemia
  3. Patients who were informed about the purpose, method, effects, risks of this clinical study and have provided a written consent form signed by him/herself or by a representative
  4. those who show an LDL-C level of 250 mg/dL or below and a TG level of less than 350 mg/dL at the run-in period (Week -1), and fall under the criterion of requiring the administration of antidyslipidemic drug of NCEP ATP III

Exclusion criteria

Exclusion Criteria:

  1. Patients with to the product or its ingredients
  2. Those with an uncontrolled hypertension (SBP ≧ 180 mmHg or DBP ≧ 100 mmHg)
  3. Those with a history of unstable angina, myocardial infarction, , cerebral vascular disease, coronary artery bypass or coronary intervention within 3 months of screening date
  4. Those with a history of malignant tumor within 5 years
  5. Those with a history of myopathy or rhabdomyolysis
  6. Those who show confirmed laboratory test results (1) Patients showing or ALT level of greater than 2 times the institutional or those with active liver disease or chronic hepatitis (2) A serum creatinine level greater than 2 times the institutional upper limit of normal (3) > 9% (4) Those with TSH level of greater than 1.5 times the institutional upper limit of normal (5) Those with CK level greater than 2 times the institutional upper limit of normal (However, except for an increase caused by a recent trauma, intramuscular injection or strenuous exercise)
  7. Those who were given, within 4 weeks prior to the baseline (8 weeks in case of fibrate) or are expected to be given during the study period, a drug that can have an effect on the efficacy assessment of the clinical study (eg: antidyslipidemic drug (statins, ezetimibe, fibrates, BAS, nicotinic acid and derivative, etc.), systemic glucocorticosteroids, steatolytic enzyme inhibitor, cyclosporine, proteinase inhibitor, macrolide class antibiotics, etc.)
  8. Patients who were given estrogen within 3 months from the screening or those who are expected to be given an administration during the study period. (However, a patient who is under a hormone replacement therapy (HRT) will be allowed if no dose change is expected in the course of the clinical study.)
  9. Those with a history of alcohol or drug abuse
  10. Patients with a hereditary disorder of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
  11. Pregnant or breast-feeding women
  12. Women of or men who do not intend to use an adequate measure during the study period and for 4 weeks after the end of the study(Adequate contraception: Administration and transplantation of a progestin-only contraceptive pill, intrauterine device, condom, spermicidal agent, etc.)
  13. Patients who participated in another clinical study within 3 months from the screening date or have not had a of at least 5 times the half-life of the active ingredient of the previously administered investigational product, whichever is longer
  14. Those with drug malabsorption
  15. Patients who has been judged by the investigator to be ineligible to participate in the clinical study
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Investigator)
Enrollment
382 participants (actual)

Study arms

  • Experimental
    RSV5mg + EZE 10mg

    Rosuvastatin 5mg/Ezetimibe 10mg

    Drug: Rosuvastatin · Drug: Ezetimibe

  • Active comparator
    RSV5mg

    Rosuvastatin 5mg

    Drug: Rosuvastatin

  • Experimental
    RSV10mg + EZE10mg

    Rosuvastatin 10mg/ Ezetimibe 10mg

    Drug: Rosuvastatin · Drug: Ezetimibe

  • Active comparator
    RSV10mg

    Rosuvastatin 10mg

    Drug: Rosuvastatin

  • Experimental
    RSV20mg + EZE10mg

    Rosuvastatin 20mg/Ezetimibe 10mg

    Drug: Rosuvastatin · Drug: Ezetimibe

  • Active comparator
    RSV20mg

    Rosuvastatin 20mg

    Drug: Rosuvastatin

Interventions

06

What researchers measure

Primary outcomes

  1. Percent change from baseline to 8 week in LDL-Cholesterol

    Time frame: baseline and 8 week

Secondary outcomes

  1. Percent change from baseline to 4 week in LDL-Cholesterol

    Time frame: baseline and 4 week

  2. The change in the LDL-C level from the baseline to Week 4 and Week 8

    Time frame: baseline to 4 and 8 week

  3. The change and percent change in the levels of TC, TG, HDL-C, non-HDL-C, apolipoprotein B, and hs-CRP from the baseline to Week 4 and Week 8

    Time frame: baseline to 4 and 8 week

  4. The change and percent change in the ratios of LDL-C/HDL-C, TC/HDL-C, non-HDL-C/HDL-C, and Apo B/Apo A-I from the baseline to Week 4 and Week 8

    Time frame: baseline to 4 and 8 week

  5. The ratio of the subjects who have reached the target LDL-C level according to the NCEP ATP(National Cholesterol Education Program Adult Treatment Panel) III Guideline at Week 4 and Week 8

    Time frame: baseline to 4 and 8 week

07

Study locations

20 sites
  • Chungbuk National University Hospital
    Cheongju-si, Korea, Republic of
  • Yeungnam University Medical Center
    Daegu, Korea, Republic of
  • Chungnam National University Hospital
    Daejeon, Korea, Republic of
  • Dongguk University Ilsan Hospital
    Goyang-si, Korea, Republic of
  • Hallym University Dongtan Sacred Heart Hospital
    Hwaseong-si, Korea, Republic of
  • Gachon University Gil Medical Center
    Incheon, Korea, Republic of
  • Inha University Hospital
    Incheon, Korea, Republic of
  • Seoul National University Bundang Hospital
    Seongnam-si, Korea, Republic of
  • Boramae Hospital
    Seoul, Korea, Republic of
  • Chung-Ang University Hospital
    Seoul, Korea, Republic of
  • Gangnam Severance Hospital
    Seoul, Korea, Republic of
  • Hanyang University Hospital
    Seoul, Korea, Republic of
  • Kangbuk Samsung Hospital
    Seoul, Korea, Republic of
  • Korea University Anam Hospital
    Seoul, Korea, Republic of
  • Korea University Guro Hospital
    Seoul, Korea, Republic of
  • KyungHee University Hospital
    Seoul, Korea, Republic of
  • Seoul National University Hospital
    Seoul, Korea, Republic of
  • Soon Chun Hyang University Hospital Seoul
    Seoul, Korea, Republic of
  • Ajou University Hospital
    Suwon-si, Korea, Republic of
  • Wonju Severance Christian Hospital
    Wŏnju, Korea, Republic of
08

References and documents

Publications

  • Kim W, Yoon YE, Shin SH, Bae JW, Hong BK, Hong SJ, Sung KC, Han SH, Kim W, Rhee MY, Kim SH, Lee SE, Hyon MS, Hwang GS, Son JW, Kim JY, Kim MK, Kim SW, Park JH, Shin JH, Park CG. Efficacy and Safety of Ezetimibe and Rosuvastatin Combination Therapy Versus Those of Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia. Clin Ther. 2018 Jun;40(6):993-1013. doi: 10.1016/j.clinthera.2018.04.015. Epub 2018 May 30. PubMed 29857919 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2014 to primary completion in Nov 2015, 13 months.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 13 months is below that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2017
First posted
Sep 19, 2017
StartActual
Oct 13, 2014
Primary completionActual
Nov 19, 2015
CompletionActual
Nov 19, 2015
Last update
Sep 19, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03288038
Responsible party
Sponsor
First posted
Sep 19, 2017
Start date
Oct 13, 2014
Primary completion
Nov 19, 2015
Completion
Nov 19, 2015
Last update
Sep 19, 2017

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ezetimibe

Start the discussion